Terminated PHASE3 INTERVENTIONAL 2-arm NCT00939276

Macular Edema Incidence/Severity Reduction With Nevanac

Sponsor: Alcon Research

Interventions Nepafenac ophthalmic suspension vehicle Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)

Updated 7 times since 2017 Last updated: Oct 18, 2012 Started: Aug 31, 2009 Primary completion: May 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Patient recruitment difficulties

Other terminated trials from Alcon Research

See all terminations from Alcon Research

Other Diabetic Retinopathy trials with similar outcome

Browse all Diabetic Retinopathy trials

This PHASE3 trial investigates Diabetic Retinopathy and is currently terminated or withdrawn. Alcon Research leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alcon Research

Data source: Alcon Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fort Worth, United States